THUY-VAN NGUYEN: Open Payments
NPI 1962438333 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,201 in 44 payments from 11 companies in 2025. Trend: 2023 $254 · 2024 $913 · 2025 $1,201
Food & beverage: $1,201
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $345 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $228 |
| Amgen Inc. | 9 | $222 |
| Sumitomo Pharma America, Inc. | 9 | $146 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $66 |
| PFIZER INC. | 2 | $55 |
| Lilly USA, LLC | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Novo Nordisk Inc | 1 | $19 |
Products named: JARDIANCE, GEMTESA, REPATHA, BREZTRI, AIRSUPRA, FARXIGA, Kerendia, PREVNAR 20.
Industry payments across TX — which companies pay providers there.
